NRDE2 deficiency impairs homologous recombination repair and sensitizes hepatocellular carcinoma to PARP inhibitors

被引:1
|
作者
Wang, Yahui [1 ,2 ]
Liu, Xinyi [1 ]
Zuo, Xianbo [3 ]
Wang, Cuiling [1 ]
Zhang, Zheng [1 ]
Zhang, Haitao [1 ]
Zeng, Tao [4 ]
Chen, Shunqi [1 ]
Liu, Mengyu [1 ]
Chen, Hongxia [1 ]
Song, Qingfeng [5 ]
Li, Qi [1 ,6 ]
Yang, Chenning [1 ]
Le, Yi [7 ]
Xing, Jinliang [8 ]
Zhang, Hongxin [2 ,9 ]
An, Jiaze [10 ]
Jia, Weihua [11 ,12 ]
Kang, Longli [13 ]
Zhang, Hongxing [6 ]
Xie, Hui [14 ]
Ye, Jiazhou [15 ]
Wu, Tianzhun [15 ]
He, Fuchu [2 ]
Zhang, Xuejun [16 ,17 ]
Li, Yuanfeng [1 ]
Zhou, Gangqiao [1 ,18 ]
机构
[1] Beijing Inst Radiat Med, Natl Ctr Prot Sci Beijing, Beijing Proteome Res Ctr, State Key Lab Med Prote, Beijing, Peoples R China
[2] Beijing Inst Lifeom, Natl Ctr Prot Sci Beijing, Beijing Proteome Res Ctr, State Key Lab Med Prote, Beijing, Peoples R China
[3] China Japan Friendship Hosp, Dept Dermatol, Dept Pharm, Beijing, Peoples R China
[4] Chinese Peoples Liberat Army Gen Hosp, Fac Hepatobiliary Pancreat Surg, Med Ctr 1, Beijing, Peoples R China
[5] Guangxi Med Univ, Affiliated Canc Hosp, Nanning, Guangxi, Peoples R China
[6] Univ South China, Sch Med, Dept Neurosci, Hengyang, Hunan, Peoples R China
[7] Chinese Peoples Liberat Army Gen Hosp, Dept Hepatobiliary Surg, Med Ctr 5, Beijing, Peoples R China
[8] Air Force Med Univ, Expt Teaching Ctr Basic Med, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China
[9] Air Force Med Univ, Tangdu Hosp, Dept Pain Treatment, Xian, Shaanxi, Peoples R China
[10] Air Force Med Univ, Xijing Hosp, Dept Hepatobiliary Surg, Xian, Shaanxi, Peoples R China
[11] State Key Lab Oncol Southern China, Guangzhou, Guangdong, Peoples R China
[12] Sun Yat Sen Univ, Dept Expt Res, Canc Ctr, Guangzhou, Guangdong, Peoples R China
[13] Xizang Minzu Univ, Sch Med, Key Lab Mol Genet Mech & Intervent Res High Altitu, Key Lab High Altitude Environm & Genes Related Dis, Xianyang, Shaanxi, Peoples R China
[14] Chinese Peoples Liberat Army Gen Hosp, Dept Intervent Oncol, Med Ctr 5, Beijing, Peoples R China
[15] Guangxi Med Univ, Guangxi Liver Canc Diag & Treatment Engn & Technol, Dept Hepatobiliary & Pancreat Surg, Canc Hosp, Nanning, Guangxi, Peoples R China
[16] Anhui Med Univ, Affiliated Hosp 1, Dept Dermatol, Hefei, Anhui, Peoples R China
[17] Anhui Med Univ, Affiliated Hosp 1, Inst Dermatol, Hefei, Anhui, Peoples R China
[18] Nanjing Med Univ, Collaborat Innovat Ctr Personalized Canc Med, Ctr Global Hlth, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China
来源
CELL GENOMICS | 2024年 / 4卷 / 05期
基金
中国国家自然科学基金;
关键词
GENOME-WIDE ASSOCIATION; DNA-REPAIR; SUSCEPTIBILITY LOCUS; READ ALIGNMENT; CANCER; EXPRESSION; NBS1; PATHOGENICITY; POLYMORPHISM; FRAMEWORK;
D O I
10.1016/j.xgen.2024.100550
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
To identify novel susceptibility genes for hepatocellular carcinoma (HCC), we performed a rare -variant association study in Chinese populations consisting of 2,750 cases and 4,153 controls. We identified four HCCassociated genes, including NRDE2 , RANBP17 , RTEL1 , and STEAP3 . Using NRDE2 (index rs199890497 [p.N377I], p = 1.19 3 10 - 9 ) as an exemplary candidate, we demonstrated that it promotes homologous recombination (HR) repair and suppresses HCC. Mechanistically, NRDE2 binds to the subunits of casein kinase 2 (CK2) and facilitates the assembly and activity of the CK2 holoenzyme. This NRDE2-mediated enhancement of CK2 activity increases the phosphorylation of MDC1 and then facilitates the HR repair. These functions are eliminated almost completely by the NRDE2-p.N377I variant, which sensitizes the HCC cells to poly(ADP-ribose) polymerase (PARP) inhibitors, especially when combined with chemotherapy. Collectively, our findings highlight the relevance of the rare variants to genetic susceptibility to HCC, which would be helpful for the precise treatment of this malignancy.
引用
收藏
页数:34
相关论文
共 50 条
  • [41] XRCC8 mutation causes hypersensitivity to PARP inhibition without Homologous recombination repair deficiency
    Maeda, Junko
    Haskins, Jeremy S.
    Kato, Takamitsu A.
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2023, 826
  • [42] Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
    Chopra, Neha
    Tovey, Holly
    Pearson, Alex
    Cutts, Ros
    Toms, Christy
    Proszek, Paula
    Hubank, Michael
    Dowsett, Mitch
    Dodson, Andrew
    Daley, Frances
    Kriplani, Divya
    Gevensleben, Heidi
    Davies, Helen Ruth
    Degasperi, Andrea
    Roylance, Rebecca
    Chan, Stephen
    Tutt, Andrew
    Skene, Anthony
    Evans, Abigail
    Bliss, Judith M.
    Nik-Zainal, Serena
    Turner, Nicholas C.
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [43] Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
    Neha Chopra
    Holly Tovey
    Alex Pearson
    Ros Cutts
    Christy Toms
    Paula Proszek
    Michael Hubank
    Mitch Dowsett
    Andrew Dodson
    Frances Daley
    Divya Kriplani
    Heidi Gevensleben
    Helen Ruth Davies
    Andrea Degasperi
    Rebecca Roylance
    Stephen Chan
    Andrew Tutt
    Anthony Skene
    Abigail Evans
    Judith M. Bliss
    Serena Nik-Zainal
    Nicholas C. Turner
    Nature Communications, 11
  • [44] BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
    Sun, Chaoyang
    Yin, Jun
    Fang, Yong
    Chen, Jian
    Jeong, Kang Jin
    Chen, Xiaohua
    Vellano, Christopher P.
    Ju, Zhenlin
    Zhao, Wei
    Zhang, Dong
    Lu, Yiling
    Meric-Bernstam, Funda
    Yap, Timothy A.
    Hattersley, Maureen
    O'Connor, Mark J.
    Chen, Huawei
    Fawell, Stephen
    Lin, Shiaw-Yih
    Peng, Guang
    Mills, Gordon B.
    CANCER CELL, 2018, 33 (03) : 401 - +
  • [45] Homologous recombination deficiency in the CCLE cell lines correlates with in vitro resistance to platinum agents and PARP inhibitors
    Takamatsu, Shiro
    Matsumura, Noriomi
    CANCER RESEARCH, 2023, 83 (07)
  • [46] PARP Inhibitors in Pancreatic Cancer with Homologous Recombination Repair Gene Mutations: A Single-Institution Experience
    Miao, Ruoyu
    Blue, Kirsten
    Sommerer, Katelyn
    Shah, Anand
    Bottiglieri, Sal
    del Cueto, Alex
    Berry, Darcy K.
    Ho, Teresa T.
    Hicks, James Kevin
    Kim, Dae Won
    CANCERS, 2024, 16 (20)
  • [47] PARP inhibitors in pancreatic cancer with homologous recombination repair gene mutations: A single-institution experience
    Miao, R.
    Yu, J.
    Blue, K.
    Sommerer, K.
    Shah, A.
    Bottiglieri, S.
    Ho, T.
    Hicks, K.
    Kim, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S146 - S146
  • [48] Real-world effectiveness of PARP inhibitors (PARPi) in metastatic castration-resistant prostate cancer (mCRPC) by genomic homologous recombination repair (HRR) alterations and homologous recombination deficiency signature (HRDsig).
    Triner, Daniel
    Graf, Ryon
    Gjoerup, Ole
    Tukachinsky, Hanna
    Ross, Jeffrey S.
    Cheng, Heather H.
    Pritchard, Colin C.
    Zurita, Amado J.
    Mateo, Joaquin
    Cieslik, Marcin
    Morgan, Todd Matthew
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 186 - 186
  • [49] Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors
    Amin, Oreekha
    Beauchamp, Marie-Claude
    Abou Nader, Paul
    Laskov, Ido
    Iqbal, Sanaa
    Philip, Charles-Andre
    Yasmeen, Amber
    Gotlieb, Walter H.
    BMC CANCER, 2015, 15
  • [50] Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors
    Oreekha Amin
    Marie-Claude Beauchamp
    Paul Abou Nader
    Ido Laskov
    Sanaa Iqbal
    Charles-André Philip
    Amber Yasmeen
    Walter H. Gotlieb
    BMC Cancer, 15